anti-HER2/anti-AXL bispecific ADC(AbTis)

N/A

Report date: 2026/05/27 17:57:53

Base Information

Drug Nameanti-HER2/anti-AXL bispecific ADC(AbTis)
Drug Alias Nameanti-HER2/AXL bispecific antibody-drug conjugate(AbTis)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-HER2Anti-AXL receptor tyrosine kinase
TargetsReceptor protein-tyrosine kinase erbB-2AXL receptor tyrosine kinase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbTis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAbTis Co LtdDong-A ST Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A